Agile Therapeutics (NASDAQ:AGRX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Tuesday. They currently have a $8.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 132.56% from the stock’s previous close.
A number of other brokerages have also weighed in on AGRX. Cantor Fitzgerald reiterated a “buy” rating and issued a $5.00 price objective on shares of Agile Therapeutics in a research report on Friday, December 22nd. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Thursday, December 28th. Janney Montgomery Scott lowered Agile Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 28th. Finally, William Blair lowered Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $9.00.
Shares of Agile Therapeutics (NASDAQ:AGRX) opened at $3.44 on Tuesday. Agile Therapeutics has a 1 year low of $1.93 and a 1 year high of $5.60. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.14.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/13/hc-wainwright-reaffirms-buy-rating-for-agile-therapeutics-agrx.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.